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Background: Glucose-6-phosphate dehydrogenase (G6PD) deficiency is a common human enzyme deficiency. It is
characterized by abnormally low levels of G6PD activity. Individuals with G6PD deficiency are at risk of undergoing
acute haemolysis when exposed to 8‐aminoquinoline-based drugs, such as primaquine. For this reason it is
imperative to identify individuals with G6PD deficiency prior to administering these anti-malarial drugs. There is a
need for the development and evaluation of point-of-care G6PD deficiency screening tests suitable for areas of the
developing world where malarial treatments are frequently administered. The development and evaluation of new
G6PD tests will be greatly assisted with the availability of specimen repositories.
Methods: Cryopreservation of erythrocytes was evaluated as a means to preserve G6PD activity. Blood specimens
from 31 patients including ten specimens with normal G6PD activity, three with intermediate activity, and 18 with
deficient activity were cryopreserved for up to six months.
Results: Good correlation in G6PD activity between fresh and cryopreserved specimens (R2 = 0.95). The
cryopreserved specimens show an overall small drop in mean G6PD activity of 0.23 U/g Hb (P=0.23). Cytochemical
staining showed that intracellular G6PD activity distribution within the red blood cell populations is preserved
during cryopreservation. Furthermore, the mosaic composition of red blood cells in heterozygous women is also
preserved for six months or more. The fluorescent spot and the BinaxNOW qualitative tests for G6PD deficiency also
showed high concordance in G6PD status determination between cryopreserved specimens and fresh specimens.
Conclusions: A methodology for establishing a specimen panel for evaluation of G6PD tests is described. The
approach is similar to that used in several malaria research facilities for the cryopreservation of parasites in clinical
specimens and axenic cultures. Specimens stored in this manner will aid both the development and evaluation of
current and emerging G6PD tests. The availability of G6PD tests is a critical bottleneck to broader access to drugs
that confer radical cure of Plasmodium vivax, a requirement for elimination of malaria.
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Glucose-6-phosphate dehydrogenase (G6PD) deficiency
is the most commonly found human enzyme deficiency,
affecting over 400 million people worldwide [1-4]. It is
characterized by abnormally low levels of G6PD activity.
Individuals with diminished G6PD activity are susceptible
to cellular oxidative damage and can exhibit symptoms in-
cluding haemolytic anaemia and jaundice in response to a
number of causes, most commonly infection or exposure
to certain medications. In particular, treatment with anti-
malarial drugs such as those in the 8‐aminoquinolone
group (e g, primaquine, pamaquine and tafenoquine)
can cause acute haemolysis in people with G6PD defi-
ciency [4,5]. Primaquine is also currently the only drug
available that is capable of radical cure of Plasmodium
vivax. Unfortunately, the prevalence map for G6PD
deficiency overlaps significantly with that for P. vivax
prevalence, possibly due to an evolutionary advantage
in people with G6PD deficiency against severe malaria
morbidity [6]. Thus, people who most need these drugs
have a relatively high chance of also carrying the G6PD
deficiency trait, putting them at risk of adverse reactions.
As malaria programmes move towards elimination,
radical cure of P. vivax becomes more critical, and the
widespread use of 8-aminoquinolones will be essential.
A major bottleneck to the adoption of these drugs is
determining the G6PD status of a patient presenting
with malaria. There is a need for a G6PD deficiency test
that can be used in the same context of malaria rapid
diagnostic tests. The gold standard for G6PD testing is
a quantitative test that measures nicotinamide adenine
dinucleotide phosphate production by the enzyme with
a UV-spectrophotometer, and the standard of care is
the fluorescent spot test, which requires a UV lamp
and a water bath. Neither of these tests is really amenable
to the point of care. There is one commercial test, the
Alere BinaxNOW test, on a lateral flow test platform, but
it is too expensive and the working temperature is too low
to be practical for adoption in malaria-endemic regions
[7]. There is a second test on the same platform that is
in late-stage development and evaluation [8]. Development
and evaluation of these tests would benefit greatly from
the availability of repositories of specimens highly char-
acterized for G6PD activity and genotype.
Cryopreservation of red blood cells has been an essential
technique used in blood banks for many years. The
cryopreserved red blood cells are often used in trans-
fusions and in serological testing. Many blood group
reference laboratories have the ability to freeze, recon-
stitute and analyse red blood cells that were collected
months or years earlier [9-11]. Over the years several
methods have been used to preserve the metabolic
functions of red blood cells [12,13]. In this report, the
feasibility of developing a G6PD specimen repository bycryopreservation is evaluated. Enzyme stability is demon-
strated by quantitative and qualitative G6PD enzyme
assays. G6PD activity distributions inside the red blood
cells are also preserved as demonstrated by flow cytome-
try. The methods presented in this article are very similar
to those used to cryopreserve blood-stage Plasmodium
parasite derived from clinical specimens or axenic culture,
and is, therefore, already familiar to several malaria clinical
research facilities [14,15].
Methods
Human subjects and specimen collection
All specimens were sourced through Bioreclamation, Inc
(Westbury, NY, USA) and were collected from voluntary
donors after signed consent under institutional review
board protocol 2010–017 IRB. Specimens arrived at
PATH in 5-mL glass ethylenediaminetetraacetic acid
anticoagulant venipuncture vacuum tubes on cold packs
and were stored at 4°C. Specimen processing took place
between two and four days after original blood draw.
Cryopreservation and thawing protocol
Freezing red blood cells
A glycerol-based protocol for cryopreservation of red
blood cells was used [13]. A total of 6 mL of whole
blood was transferred to a 15- mL test tube and
centrifuged 1,000/g for 5 min. The plasma and buffy
coats were aspirated. The red blood cells were washed
with 0.9% saline, centrifuged at 1,000/g for 5 min, and
the supernatant aspirated. The cells were washed until
the supernatant was clear. Two volumes of Glycerolyte
57 (Baxter, USA) were added to one volume of red blood
cell pellet in the following way: first, 20% of Glycerolyte
57 was added dropwise to the red blood cells while
gently mixing and incubated for 10 min with gentle
rocking. The remaining Glycerolyte 57 (80%) was added
dropwise while gently mixing and was incubated for an
additional 10 min with gentle rocking to give a final
40% weight by volume glycerol concentration. The 1.5-
mL aliquots of glycerolyte-treated red blood cells were
transferred into cryovials stored at −80°C.
Thawing red blood cells
The cryovials were removed from −80°C and thawed at
room temperature [13]. The red blood cells were trans-
ferred to a 5-mL test tube. They were centrifuged at
1,000/g for 2 min, and the glycerol freezing solution was
aspirated. Then 0.16 mL of 12% saline for each 0.5 mL
of red blood cell pellet volume was added dropwise and
with gentle shaking over a period of 5 min. The red
blood cells were left standing for 3 min at room
temperature. Next, 0.5 mL of 0.2% dextrose/0.9% saline
was added dropwise with gentle shaking per 0.5 mL of
red blood cell pellet. The red blood cells were left sitting
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0.5 mL of 0.2% dextrose/0.9% saline and letting the red
blood cells stand undisturbed at room temperature —
was repeated until the final volume of solution added to
the test tube was 4 mL. The red blood cells were then
centrifuged at 1,000/g for 1 min, and 0.5 mL of the
supernatant was aspirated. The red blood cells were
resuspended by repeatedly inverting the test tube. The
amount of 0.5 mL of 0.2% dextrose/0.9% saline was
slowly added dropwise, followed by gentle shaking. After
the 0.2% dextrose/0.9% saline was added, the red blood
cells sat for 2 min at room temperature. This process —
centrifuging, removing the supernatant, resuspending
the red blood cell pellet, adding a volume of 0.2%
dextrose/0.9% saline equal to what was aspirated and
then standing for 1 min — was repeated with the
following volumes: 1, 1.5, 2, and 4 mL. Finally, the red
blood cells were centrifuged at 1,000/g for 1 min, and
all of the supernatant was aspirated. The red blood cells
were washed with 0.9% saline until no haemolysis was
observed.
Quantitative G6PD trinity assay
All specimens were characterized for G6PD activity in
duplicate using the quantitative G6PD kit from Trinity
(Cat No 345-B Trinity Biotech Plc, Ireland). Normal,
intermediate and deficient Trinity controls (Cat No
G6888, G5029, G5888) were run using the same method
each day the assay was run. The quantitative assays were
run per the kit instructions. The enzyme activity was
determined at 30°C using a temperature regulated spec-
trophotometer (UV-1800 Shimadzu) by measuring the
change in rate in absorbance at 340 nm over 5 min for
reaction solutions held in UV disposable cuvettes (Brand
Cat No 759150). All G6PD activity rates are provided in
U/gHb. Haemoglobin concentration was determined
using a Hemocue (Fisher Scientific, USA, Hb 201+ Ana-
lyzer, Hemocue Inc, No 121721, Cat No 22-601-007).
Trinity fluorescent spot test – G6PD qualitative assay
Each individual specimen and Trinity normal, intermediate
and deficient controls (Cat No G6888, G5029 and G5888)
were run at three different time points (at time zero,
after 5 min and after 10 min) using Whatman No 1 filter
paper (Cat No 1001–150) on the qualitative G6PD
assay Trinity fluorescent spot test kit (Cat No 203-A
Trinity Biotech Plc, Ireland). Controls were run each
day that specimens were run.
BinaxNOW card test – G6PD qualitative test
Reproducibility of G6PD activity with fresh and thawed
specimens on the lateral flow test platform was evalu-
ated using the BinaxNOW G6PD Test (Alere, USA,
Cat No 780–000). The test can only be run between18°C and 25°C. G6PD Trinity controls (normal control
G6888 and deficient control G5888) were run periodic-
ally to ensure quality performance of the BinaxNOW
G6PD test.
Flow cytometry protocol
Whole blood specimens were characterized for intra-
cellular G6PD activity by flow cytometry as described
previously [16]. This method allows observation of mosaic
red blood cell populations in specimens from females
by looking at the activity of G6PD in individual eryth-
rocytes. Ten microliters of 50% haemotocrit red blood
cell suspension was diluted into 90 μL of 0.9% NaCl and
was combined with 100 μL of sodium nitrite (0.125 M,
Sigma, USA) and incubated at room temperature for
20 min. Samples were washed three times with phos-
phate-buffered saline (PBS) at 3,000 rpm for 3 min and
resuspended in 100 μL of PBS. The red blood cells were
then combined with 18 μL of glucose (0.28 M) in
phosphate-buffered saline and 6 μL of Nile Blue Sulphate
(0.01% Sigma, USA) and incubated at 37°C for 90 min
with the lids of the Eppendorf tubes open. After the
incubation, 2.5 μL of 0.4 M potassium cyanide (Sigma,
USA) was added and incubated for 5 min. Five microliters
of each sample were added to 100 μL of 3% hydrogen
peroxide in PBS, agitated vigorously by hand, and washed
two times in PBS. Specimens were analysed using a
FACScaliber™ cytometer, 10,000 events, in the FL1 channel
533 +− 30 nm.
Statistical methods
All statistical analyses were conducted in Stata 12.0
(Statacorp, College Station, TX, USA). The mean and
the standard deviation (SD) of the quantitative Trinity
G6PD assay were determined for all specimens at Day 0,
and all specimens were thawed between Day 0 and Day
200; summary statistics were also calculated for speci-
mens stratified by the following cryopreservation time
intervals: i) specimens thawed between Day 0 and Day
30 after cryopreservation, ii) specimens thawed between
Day 31 and Day 89 after cryopreservation, and iii) speci-
mens thawed between Day 90 and Day 200 after cryo-
preservation. A paired t-test was used to test whether
there was a significant difference between the mean
assay results between Day 0 and the thaw date.
To determine the correlation between the quantitative
Trinity G6PD assays pre- and post-cryopreservation,
data from all cryopreserved specimens were plotted
against data from Day 0. A linear regression line that
best fit the data was plotted, and the corresponding R2
was calculated. Bland-Altman analyses were conducted
to visually assess the agreement between the test results
over time. The mean differences, standard deviation of
the difference, and a 95% tolerance-bound mean dif-
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and plotted.
In order to determine the correlation between qualita-
tive test results, pre- and post-thaw BinaxNOW and
Trinity fluorescent spot test results were compared using
a McNemar’s and McNemar-Bowker test, respectively.
Finally, for a subset of four specimens for which three
additional test results (in addition to Day 0) were avail-
able, generalized estimating equations with an exchange-
able correlation matrix and robust standard errors were
used to estimate the combined effect for the difference




Blood specimens from 31 patients (21 males and ten
females) were cryopreserved as described in Methods.
Multiple aliquots of the blood specimens were stored
at −80°C. The blood specimens were then thawed at
multiple time points between Day 0 and Day 200 after
cryopreservation. All specimens were characterized for
G6PD activity with the Trinity quantitative assay as
well as by flow cytometry assay as described in
Methods, both prior to cryopreservation (Day 0 data)
and just after thawing. By the quantitative assay, ten
specimens had normal activity, three were of intermediate
activity, and 18 were deficient in G6PD activity (Table 1).
By flow cytometry, four of the females displayed a popu-
lation of red blood cells with a high G6PD activity and
a population of red blood cells with a low G6PD activ-
ity, characteristic of females who are heterozygous for
G6PD. A subset of these specimens was also tested by
two qualitative tests, the fluorescent spot test and the
BinaxNOW test.
G6PD activity in cryopreserved specimens
The mean G6PD activity for the fresh blood samples
from the 31 patients used in this study was 4.10 U/gHb
(Table 2). Quantitative Trinity G6PD activity levels were
determined for a total of 51 cryopreserved specimens at
various time intervals between Day 0 and Day 200
(Table 2). Of these, 21 were thawed and tested between
Day 0 and Day 30, 20 were thawed and tested betweenTable 1 Characteristics of the 31 specimens used to evaluate
Phenotype by activity Male Female Total Pheno
Normal 6 4 10 Norm
Intermediate 0 3 3 Heter
Deficient 15 3 18 Defici
Total 21 10 31 Total
G6PD activity was determined by spectrophotometry with a quantitative assay. G6PDay 31 and Day 89, and ten were thawed and tested
between Day 90 and Day 200. For the entire combined
sample set, there was a small drop in mean G6PD ac-
tivity between Day 0 and the thaw date (0.232 U/gHb,
P= 0.233). Similar changes in mean G6PD activity were
observed for specimens cryopreserved up to 30 days
and between 90 and 200 days, whilst the G6PD activity
for specimens cryopreserved for 31 to 89 days was not
significantly different to the mean G6PD activity at Day
0 (P= 0.629).
A scatterplot showing the correlations of G6PD activity
of specimens cryopreserved for different time intervals
vs Day 0 (fresh specimens) are shown in Figure 1A.
When compared to Day 0, all specimens, including
those stratified by thaw-date interval, had strong linear
correlations (P<0.001) with R2 values ranging between
0.9404 and 0.9953. Figure 1B shows the Bland Altman
analysis, a visual comparison of test results between
cryopreservation intervals and Day 0 for all specimens.
For all cryopreserved specimens, the mean difference
is 0.23 (95% CI: (−1.83, 2.29)), suggesting that the
correlations are not biased. Similar results were ob-
served when stratified by cryopreservation time inter-
val. A subset of four specimens fell out of the 1.96
SD range.
For a subset of four specimens, three with normal ac-
tivity and one deficient in G6PD activity, data were
available for Day 0 plus three additional cryopreser-
vation time intervals (Figure 2). Results from a gene-
ralized estimating equations model on repeated test
results on four specimens over time indicate that time
was not a significant factor in predicting the test results
at any thaw date (Table 3).G6PD activity distribution in the red blood cell population
Intracellular G6PD activity was observed by cytochemical
staining of the cells as described previously and in the
methods [16]. The distribution of G6PD activity within
the red blood cell population of fresh specimens and
cryopreserved specimens was observed by flow cytometry
(Figure 3). Only minor changes in profiles are observed
which are possibly due to the cryopreservation and
thawing process (Figure 3).G6PD activity within cryopreserved red blood cells [16]
type by cytochemical staining Male Female Total
al 6 3 9
ozygous - 4 4
ent 15 3 18
21 10 31
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Figure 1 Correlation in G6PD activity values between fresh specimens (Day 0) and cryopreserved specimens. (A) Direct comparison of
G6PD activities for fresh and cryopreserved specimens is shown. The solid line indicates the linear regression fit. (B) Bland-Altman plot for
differences in G6PD activity between fresh and cryopreserved specimens.
Table 2 Mean and standard deviation (SD) of G6PD enzyme activity (in U/gHb) at Day 0 and at thaw date
Cryopreservation time intervals (days) specimens
0 to 30 31 to 89 90 to 200 Sum (0 to 200)
Number of cryopreserved specimens (Number of corresponding fresh blood specimens) 21 (14) 20 (20) 10 (10) 51 (31)
Meana (SD) G6PD activity at Day 0 4.57 (4.22) 4.40 (3.80) 4.74 (4.05) 4.10 (3.90)
Meanb (SD) G6PD activity at thaw date 4.04 (4.33) 4.55 (4.68) 3.91 (3.93) 3.87 (4.41)
Mean difference (SD) between Day 0 & thaw date 0.53 (0.46) −0.15 (0.31) 0.84 (0.09) 0.23 (1.05)
P value* <0.001 0.629 <0.001 0.233
Meana (SD) G6PD activity at Day 0 is the mean of the activities in fresh blood from which cryopreserved aliquots were used over a given time interval.
Meanb (SD) G6PD activity at thaw date is the mean of the activities in the cryopreserved specimens thawed over a given time interval.
*Paired t test P value.


















































 Thaw date interval
Figure 2 Longitudinal G6PD activity recovered from three cryopreserved aliquots of the same specimen. Data are shown for four
specimens, three with normal G6PD activity and one with deficient G6PD activity. Specimens were cryopreserved at a single date in multiple
aliquots. Aliquots of cryopreserved specimens were than thawed at multiple dates and analysed for G6PD activity. (A) Absolute G6PD activity at
thaw dates after cryopreservation and (B) Difference in G6PD activity from that at Day 0. For easy comparison the dates were normalized to Days
1, 2, and 3 in Figure 2B.
Table 3 Parameter estimates and robust standard errors
for the generalized estimating equations model of
quantitative trinity results
Parameter β coefficient Robust standard error P value
Intercept −0.50 0.350 0.153
Time (days) −0.003 0.002 0.138
Day 0 Trinity result 1.04 0.040 0.000
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The G6PD deficiency point-of-care test and the fluores-
cent spot test were performed on the stored specimens to
evaluate the performance of these tests on cryopreserved
specimens. Cryopreserved specimens were resuspended
to a 50% haematocrit, and the tests were performed as
per the product insert. Among the 21 specimens for
which pre- and post-cryopreservation BinaxNOW data
were available, there was 100% agreement in the test
results (Table 4). For the Trinity fluorescent spot test,
one specimen with normal activity by the spot test
prior to cryopreservation but a low G6PD activity by
AB
C
Figure 3 Distribution of G6PD activity within red blood cell popoulations of fresh and cryopreserved specimens. Intracellular G6PD
activity distributions as indicated by flourscence are shown for (A) a normal male, (B) heterozygous female, and (C) deficient male specimens.
Intracellular G6PD activity profiles are shown for Day 0 prior to cryopreservation and two separate dates at which the same specimen was
thawed after cryopreservation.
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intermediate after preservation. There were five specimens
which were classified as having intermediate activities
by the fluorescent spot test prior to cryopreservation
and then classified as deficient after cryopreservation.Table 4 G6PD status after cryopreservation as determined by tw
BinaxNOW G6PD deficiency test Post-cryopreserv
Normal
Fresh specimen results Normal 8
Deficient 0
Total 8
Fluorescent spot test Post-cryopreserv
Normal




* The five specimens initially characterized as intermediate by the fluorescent spotThese had all been classified as deficient by the quantitative
test both on fresh specimens and post cryopreservation
(G6PD activities of 1.27, 1.13, 1.20, 1.45, 0.12 U/g Hb). The
reasons for these discrepancies are being investigated by












test were G6PD deficient by the quantitative test.
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fluorescent spot test was 71.4%, the McNemar-Bowker
symmetry test results indicate there was no significant
difference between the test results at the two time
periods (P= 0.0498) (Table 4).
Discussion
The availability of clinically relevant specimens is critical
in diagnostic test development and evaluation. In the
case of tests for G6PD deficiency, a particular challenge
is access to specimens with intermediate and low G6PD
activity as well as heterozygous females. These are typ-
ically in low prevalence in the population and require
significant screening to identify patients with these
G6PD activity characteristics. Unfortunately, when these
specimens are obtained they must be tested within a
short time frame (seven to 14 days) [17]. Establishing a
specimen bank enriched for specimens with intermediate
G6PD activity, with deficient G6PD activity, and from
confirmed heterozygous females would be of great value
to both the development of tests for G6PD deficiency
and to their early evaluation.
Red blood cells are routinely cryopreserved for blood-
banking purposes [10,11]. The process for this results
in storage of large blood volumes far beyond what is
needed for G6PD testing. Additionally, the processes use
automated, functionally closed systems for the glycerol-
ization and deglycerolization steps, which are typically
neither available nor appropriate outside of a blood-bank
setting. Cryopreservation of red blood cells, as described
in this article, can be used to establish a specimen
repository at appropriate specimen volumes to support
the development and evaluation of G6PD tests. Good
quantitative correlation of G6PD activity in specimens
that have been stored for up to 200 days (R2 = 0.95) is
demonstrated. The specimens experience a small but
significant drop in G6PD activity: 0.23 U/g Hb differ-
ence in mean activities for all specimens. A subset of
these specimens experienced a more than two standard
deviations drop in G6PD activity after going through
the cryopreservation and thaw process (Figure 1B), this
may reflect the user dependence of the process, and as
the protocols have been optimized the frequency of
these observations have reduced. The ability to examine
G6PD activity within the red blood cells through cyto-
chemical staining is a useful means to identify heterozy-
gous female specimens [16,18-20]. Intracellular G6PD
activity distribution in the red blood cell population
was also cryopreserved remarkably well and would allow
differentiation between specimens originating from a
normal hemizygous male, a heterozygous female, and a
deficient hemizygous male. While the data presented
here demonstrates that red blood cells in EDTA can be
cryopreserved with significant consistency, cryopreservationspecifically for cytochemical staining may be improved by
using blood specimens collected in acid citrate dextrose
(ACD). Qualitative tests also showed similar performance
pre- and post-cryopreservation with discordance only
occurring with the fluorescent spot test for G6PD-
deficient specimens, which had been misclassified origin-
ally as specimens with intermediate G6PD activity by the
same test.
While the feasibility of using cryopreservation to estab-
lish specimen banks for G6PD testing has been demon-
strated, it is important to recognize that the methodology
is fairly user-dependent, complex and can definitely
benefit from small-scale, semi-automated processes to
standardize the freezing and thawing process. These
processes continue to be optimized. Other approaches
such as lyophilization should be explored further, espe-
cially if such approaches can reduce reliance on a cold
chain infrastructure [12]. Additionally there are new
technologies emerging that may provide alternative
specimen storage approaches [21].
The only tools available to the malaria community to
achieve radical cure of P. vivax and to reduce gameto-
cyte transmission are the 8-aminoquinoline-based drugs.
With the resurgence of drug resistance and a focus toward
malaria elimination, there is a greater and more urgent
need to make these drugs more widely available. This
can only happen with broader access to G6PD testing.
Current tests for G6PD deficiency do not meet this de-
mand. New G6PD tests are required, and cost-efficient
ways to support their development and evaluation will be
critical to ensure good quality products enter the market.
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